Search
Mubodina
go.drugbank.com/drugs/DB17616ExperimentalMubodina is an investigational drug developed by Adienne Pharma & Biotech. It is a recombinant human minibody directed against complement component C5.
XTL-001
go.drugbank.com/drugs/DB05405InvestigationalXTL001 is an investigational monoclonal antibody (MAb) product developed by XTL Biopharmaceuticals to evaluate the safety profile and antiviral activity of the compound in patients chronically infected
BMS-564929
go.drugbank.com/drugs/DB07286ExperimentalSo far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause.
Zilebesiran
go.drugbank.com/drugs/DB18929InvestigationalZilebesiran is under investigation in clinical trial NCT06272487 (Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care
Tiletamine
go.drugbank.com/drugs/DB11549ExperimentalVet approvedTiletamine hydrochloride, the salt form, exists as odorless white crystals.
Amubarvimab
go.drugbank.com/drugs/DB16493InvestigationalAmubarvimab (BRII-196) was under investigation in clinical trials (NCT04691180 and NCT04787211) to treat COVID-19, focusing on its safety, tolerability, and efficacy.
AP5280
go.drugbank.com/drugs/DB05112ExperimentalAP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.
Vindesine
go.drugbank.com/drugs/DB00309ApprovedInvestigationalWithdrawnVinblastine derivative with antineoplastic activity against cancer. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (antineoplastic combined chemotherapy protocols).
Apadenoson
go.drugbank.com/drugs/DB05009InvestigationalIt is developed by Bristol-Myers Squibb and is in phase II of clinical trials.